Sun Pharma to sell 100 percent stake in Japanese arm
Mumbai: Sun Pharmaceutical Industries Limited has entered into an agreement with Zaza Industrial Holdings K.K, Japan, under which Sun Pharma has agreed to sell 100% shares held in Sun Pharma Japan Technical Operations Limited, a step-down subsidiary of the Company (through its subsidiary, Sun Pharma Japan Limited).
Consequently, Sun Pharma Japan Technical Operations Limited shall cease to be a subsidiary of the Company. The expected date of completion of sale/disposal will be January 31, 2025.
Read also: Sun Pharma Laboratories Gets CDSCO Panel Nod for Etifoxine Hydrochloride Capsules study
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.